Northwire Canada EditionThursday, August 6, 2026
Sign inSubscribe
Northwire
⌕
ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2% ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2%
Earnings

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

By The Northwire Desk — AI Analysis Nov 06, 2025 · 07:30 CYBN · 8.4 CYBIN INC.
CYBN · Price

Executive Summary

  • Cybin Inc. will host a conference call and webcast on Thursday, November 13, 2025 at 8:00 a.m. ET to provide a business update and report its second‑quarter financial results for the quarter ended September 30, 2025.
  • The call can be accessed via toll‑free or international dial‑in numbers, with the webcast available after registration on the investor‑relations website.
  • This announcement signals an upcoming earnings release, which is material information for investors.

Key Details

  • Conference Call: Thursday, Nov 13, 2025 – 8:00 a.m. ET.
  • Dial‑in Numbers: 800‑245‑3047 (U.S. toll free) or 203‑518‑9765 (International).
  • Conference ID: CYBN1113.
  • Webcast Registration: Available through the link provided in the release; archived webcast will be posted on Cybin’s “Events & Presentations” page.
  • Purpose of Call: Business update and presentation of Q2 2025 financial results (quarter ended September 30, 2025).
  • Company Background (brief): Phase‑3 clinical‑stage neuropsychiatry firm developing CYB003 (deuterated psilocin analog) for major depressive disorder (Breakthrough Therapy Designation) and CYB004 (deuterated DMT) for generalized anxiety disorder, among other pipeline assets.

Notable Quotes

No executive quotes were included in the release.

Read the original news release →

More from CYBIN INC.

Dec 30, 2025 · 15:33

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Financings Dec 18, 2025 · 07:30

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Regulatory Nov 13, 2025 · 07:20

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Earnings Oct 31, 2025 · 16:19

Cybin Announces Closing of $175 Million Registered Direct Offering

Financings Oct 28, 2025 · 08:00

Cybin Announces $175 Million Registered Direct Offering

Financings